BURLINGTON, Ontario, Nov. 30, 2016 /PRNewswire/ -- Natrix Separations Inc. today announced development agreements with Merck,known as MSD outside the United States and Canada, and Sanofi to advance Natrix's new membrane-based Protein A platform for antibody purification.
The Natrix Protein A platform
Natrix CEO John Chickosky, commented, "Natrix has developed and commercialized single-use hydrogel membranes for impurity removal in polishing purification steps. This new development work for our Protein A products now provides additional capability to the toolbox for the fully single-use process for antibody production. The industry has long sought downstream solutions to match the innovation that has benefitted upstream operations. Natrix, working with our collaborators, believes we will soon be able to fill that gap."
Merck and Natrix previously collaborated on the development of Natrix's membrane purification products, including lab-scale demonstration that Natrix Protein A materials achieve capacity, selectivity and other critical performance characteristics equal to or better than best in class Protein A resins.
Under the terms of the agreements, investments by Merck and Sanofi, along with technology collaboration between the individual collaborators and Natrix, will accelerate Natrix's multi-million dollar platform commercialization program. Specific financial terms were not disclosed.
Separately, Natrix has entered into an agreement with Scil Proteins GmbH for the engineering and development of the proprietary Protein A ligand that will be integrated with Natrix's membrane technology.
About Natrix Separations, Inc.
Natrix Separations enables fast and flexible manufacturing of biopharmaceuticals through high-productivity disposable downstream processing products. The innovative Natrix HD Membranes overcome the limitations in efficiency, speed, and flexibility imposed by conventional capital-intensive approaches to chromatography. Natrix products feature well-established industry-standard chemistries, and are scalable from R&D to commercial manufacturing. Natrix is headquartered in Burlington, Ontario, Canada. For additional information, visit www.natrixseparations.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/natrix-separations-announces-collaboration-agreements-with-merck-and-sanofi-for-the-development-of-membrane-based-protein-a-purification-platform-300369980.html
SOURCE Natrix Separations Inc.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All